A change in an enzyme that puts a chemical silencing mark on DNA. The altered enzyme adds too much of the mark, which keeps a lymphoma cell locked in the state it should have grown out of. It selected a tablet, tazemetostat, until the United States approval for follicular lymphoma was withdrawn on 22 June 2026.
EZH2 is the catalytic subunit of polycomb repressive complex 2 and writes the H3K27 trimethyl mark. In lymphoma the mutations replace a single tyrosine in the SET domain, Tyr641 in the original numbering and Tyr646 in current usage. They are not simple activating mutations: the altered enzyme is better at converting the di-methyl mark to the tri-methyl mark and worse at making the first methylation, so a cell with one mutant and one wild-type allele accumulates H3K27me3 and holds the germinal-centre programme shut. This is the opposite direction to the loss-of-function EZH2 mutations found in myeloid disease, which is a standing source of confusion in the literature.
The substitutions occur in 21.7% of germinal-centre diffuse large B-cell lymphomas and 7.2% of follicular lymphomas, and are absent from the activated B-cell-like subtype (Morin 2010). EZH2 mutation with BCL2 translocation defines the EZB genetic subtype (Schmitz 2018).
In plain words · EZH2 is an enzyme that silences genes. The first drug against it, tazemetostat, treated a rare sarcoma and some lymphomas until it was withdrawn in 2026 for causing second blood cancers.
In relapsed follicular lymphoma this result used to open a treatment: tazemetostat, a tablet that blocks the altered enzyme, given accelerated approval in the United States in June 2020. In the single-arm study on its label, 69% of 42 people whose lymphoma carried the mutation responded, against 34% of 53 whose lymphoma did not. The FDA lists the follicular lymphoma approval as withdrawn on 22 June 2026, so in the United States the result no longer selects a licensed medicine; it can still matter for a trial.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
Targeted sequencing of the EZH2 SET domain, reported as mutated or wild-type. Sensitivity matters because the mutation is usually heterozygous and may be subclonal; it is normally reported from a lymphoma gene panel on tissue.
“These mutations, which result in the replacement of a single tyrosine in the SET domain of the EZH2 protein (Tyr641), occur in 21.7% of GCB DLBCLs and 7.2% of FLs and are absent from ABC DLBCLs.”
Morin et al., Nature Genetics 2010No approval uses this readout as a threshold. It is defined by Morin et al., Nat Genet 2010: somatic EZH2 Tyr641 mutations in follicular and germinal-centre diffuse large B-cell lymphoma.
| Device | Maker | Indication and sample | Drug | PMA / 510(k) |
|---|---|---|---|---|
| cobas EZH2 Mutation Test | Roche Molecular Systems, Inc. | Follicular Lymphoma Tumor - Tissue | Tazemetostat | P200014 (06/18/2020) |
Shares BCL2 rearrangement, t(14;18), The germinal centre reaction, The germinal centre: why lymphoma starts where antibodies are made, BCL-2 and the tags biomarker, lymphoma.
Shares BCL2 rearrangement, t(14;18), BCL-2, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tags biomarker, lymphoma.
Shares LymphGen and the genetic clusters of large B-cell lymphoma, Next-generation sequencing (NGS), Comprehensive genomic profiling, Diffuse large B-cell lymphoma and the tags biomarker, lymphoma.
Shares The germinal centre: why lymphoma starts where antibodies are made, Next-generation sequencing (NGS), Follicular lymphoma, Diffuse large B-cell lymphoma and the tags biomarker, lymphoma.
Shares Epigenetic reprogramming, Next-generation sequencing (NGS), Comprehensive genomic profiling, Non-Hodgkin lymphoma (all types) and the tags biomarker, lymphoma.
Shares Non-Hodgkin lymphoma (all types) and the tags biomarker, lymphoma.
Shares BCL2 rearrangement, t(14;18), BCL-2, Next-generation sequencing (NGS), Comprehensive genomic profiling and the tags biomarker, lymphoma.
Shares Next-generation sequencing (NGS), Comprehensive genomic profiling, Non-Hodgkin lymphoma (all types) and the tags biomarker, lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/